Movatterモバイル変換


[0]ホーム

URL:


WO2020013776A3 - Synergistic effect of naproxen and a gastro protective agent for the treatment of pain and inflammation - Google Patents

Synergistic effect of naproxen and a gastro protective agent for the treatment of pain and inflammation
Download PDF

Info

Publication number
WO2020013776A3
WO2020013776A3PCT/TR2019/050184TR2019050184WWO2020013776A3WO 2020013776 A3WO2020013776 A3WO 2020013776A3TR 2019050184 WTR2019050184 WTR 2019050184WWO 2020013776 A3WO2020013776 A3WO 2020013776A3
Authority
WO
WIPO (PCT)
Prior art keywords
naproxen
protective agent
inflammation
pain
treatment
Prior art date
Application number
PCT/TR2019/050184
Other languages
French (fr)
Other versions
WO2020013776A2 (en
Inventor
Mehmet Nevzat PISAK
Original Assignee
Pisak Mehmet Nevzat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pisak Mehmet NevzatfiledCriticalPisak Mehmet Nevzat
Publication of WO2020013776A2publicationCriticalpatent/WO2020013776A2/en
Publication of WO2020013776A3publicationCriticalpatent/WO2020013776A3/en

Links

Classifications

Landscapes

Abstract

The present invention relates to pharmaceutical combinations comprising naproxen and an H2 receptor antagonist as gastro-protective agent, preferably famotidine, to oral dosage forms comprising such combinations and to processes for the preparation thereof. The present invention relates also to an oral immediate release pharmaceutical composition comprising naproxen or a pharmaceutically acceptable salt thereof, a H2 receptor antagonist as a gastro protective agent and at least one carbonate.
PCT/TR2019/0501842018-03-212019-03-21Synergistic effect of naproxen and a gastro protective agent for the treatment of pain and inflammationWO2020013776A2 (en)

Applications Claiming Priority (4)

Application NumberPriority DateFiling DateTitle
TR2018039832018-03-21
TR2018/039832018-03-21
TR2018075842018-05-28
TR2018/075842018-05-28

Publications (2)

Publication NumberPublication Date
WO2020013776A2 WO2020013776A2 (en)2020-01-16
WO2020013776A3true WO2020013776A3 (en)2020-06-18

Family

ID=69142764

Family Applications (1)

Application NumberTitlePriority DateFiling Date
PCT/TR2019/050184WO2020013776A2 (en)2018-03-212019-03-21Synergistic effect of naproxen and a gastro protective agent for the treatment of pain and inflammation

Country Status (1)

CountryLink
WO (1)WO2020013776A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
EA202092800A1 (en)*2018-05-282021-04-08Мехмет Невзат Писак IMMEDIATE RELEASE PHARMACEUTICAL COMPOSITION FOR ANTI-INFLAMMATORY MEDICINES WITH FAMOTIDINE AND CARBONATE

Citations (3)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US6165506A (en)*1998-09-042000-12-26Elan Pharma International Ltd.Solid dose form of nanoparticulate naproxen
US20050249811A1 (en)*2001-06-012005-11-10Pozen Inc.Pharmaceutical compositions for the coordinated delivery of NSAIDs
US20110313009A1 (en)*2008-07-172011-12-22Horizon Pharma Usa, Inc.Nsaid dose unit formulations with h2-receptor antagonists and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US6165506A (en)*1998-09-042000-12-26Elan Pharma International Ltd.Solid dose form of nanoparticulate naproxen
US20050249811A1 (en)*2001-06-012005-11-10Pozen Inc.Pharmaceutical compositions for the coordinated delivery of NSAIDs
US20110313009A1 (en)*2008-07-172011-12-22Horizon Pharma Usa, Inc.Nsaid dose unit formulations with h2-receptor antagonists and methods of use

Also Published As

Publication numberPublication date
WO2020013776A2 (en)2020-01-16

Similar Documents

PublicationPublication DateTitle
WO2014205229A8 (en)Use of high dose pridopidine for treating huntington's disease
WO2018165404A8 (en)Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
EP3207931A3 (en)Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies
JOP20200201A1 (en)Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
EA201691454A1 (en) COMPOSITIONS OF PRIDOPIDININE MODIFIED SHIPPING
MX2021016109A (en)Methods and compositions particularly for treatment of attention deficit disorder.
NZ605469A (en)Nalbuphine-based formulations and uses thereof
NZ778223A (en)Modified release tablet formulations containing phosphodiesterase inhibitors
MX2015001917A (en)Pharmaceutical compositions of memantine.
PH12015500823A1 (en)Modified release formulations for oprozomib
WO2018027084A3 (en)Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer
PH12019502651A1 (en)Use of vibegron to treat overactive bladder
TR201721505A2 (en)The combination comprising linagliptin and metformin
MX341660B (en)Ghrelin receptor agonist for treatment of dyscrasia.
WO2008008882A3 (en)Glucocorticoid receptor modulator and methods of use
HK1203394A1 (en)Ghrelin receptor agonists for the treatment of achlorhydria
WO2020013776A3 (en)Synergistic effect of naproxen and a gastro protective agent for the treatment of pain and inflammation
PH12019502767A1 (en)Oral pharmaceutical formulations of remogliflozin
AU2016407426A1 (en)Triple combination of pure 5-HT6 receptor antagonists, Acetylcholinesterase inhibitors and NMDA receptor antagonist
PH12020500120A1 (en)Pharmaceutical compositions
WO2020032883A3 (en)Synergistic effects of a novel ketoprofen formulation including a gastro protective agent
WO2020013781A3 (en)Synergistic effect of flurbiprofen and a gastro protective agent for the treatment of pain and inflammation
MX2022002356A (en)Solid oral dosage form comprising naproxen and vitamin b12.
WO2015166418A3 (en)Pharmaceutical composition for the treatment of allopathic pain, using ketorolac tromethamine and tramadol hydrochloride as an active ingredient
GR1008819B (en)Pharmaceutical composition comprising atomoxetine and method for the preparation thereof

Legal Events

DateCodeTitleDescription
121Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number:19835156

Country of ref document:EP

Kind code of ref document:A2

NENPNon-entry into the national phase

Ref country code:DE

32PNEp: public notification in the ep bulletin as address of the adressee cannot be established

Free format text:NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 22.01.2021)

122Ep: pct application non-entry in european phase

Ref document number:19835156

Country of ref document:EP

Kind code of ref document:A2


[8]ページ先頭

©2009-2025 Movatter.jp